Cambrex Invests in New Small Scale Capacity at Its Charles City, Iowa Facility
November 08 2017 - 8:00AM
Cambrex Corporation (NYSE:CBM), the leading manufacturer of small
molecule innovator and generic Active Pharmaceutical Ingredients
(APIs), today announced that it has completed an expansion of cGMP
small scale capacity at its Charles City, Iowa plant.
The project has seen the installation of two 500
gallon glass lined reactors and creates a third small scale work
center, further increasing flexibility for customer projects.
“Small scale manufacturing has been identified
as being a crucial area where capacity is at a premium within the
industry, and this investment has been undertaken to increase our
flexibility and reduce potential project bottle necks to benefit
our customers,” commented Joe Nettleton, Vice President US
Operations, Cambrex. “This continues Cambrex’s ongoing commitment
to investing in small molecule manufacturing, ensuring that we can
meet the challenges of customer project timelines, especially at
the key development stages.”
This latest investment follows the completion of
an expansion of large scale manufacturing capabilities and an
announcement of the construction of a $24M, 4,500 sq. ft. highly
potent API (HPAPI) manufacturing facility at Charles City, which is
due to open in 2019.
Cambrex’s Charles City, Iowa facility is located
on a 45-acre site and manufactures a wide range of APIs and
pharmaceutical intermediates, including highly potent molecules and
controlled substances. The facility was recently recognized by the
Society of Chemical Manufacturers and Affiliates’ (SOCMA)
ChemStewards® program, where it exceeded key performance
requirements in federal environmental, health, safety and security
compliance. As a result, the site qualified for the program’s
highest ranking, the Excellence Tier.
About
CambrexCambrex Corporation is an innovative life
sciences company that provides products, services and technologies
to accelerate the development and commercialization of small
molecule therapeutics. The company offers Active
Pharmaceutical Ingredients (APIs), advanced intermediates and
enhanced drug delivery products for branded and generic
pharmaceuticals. Development and manufacturing capabilities include
enzymatic biotransformations, high potency APIs, high energy
chemical synthesis and controlled substances. For more
information, please visit www.cambrex.com
Contact:
Alex
Maw
Director, Marketing and
Communications
Tel: +44 7803 443
155
Email: alex.maw@cambrex.com
Cambrex (NYSE:CBM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cambrex (NYSE:CBM)
Historical Stock Chart
From Sep 2023 to Sep 2024